Xarelto (rivaroxaban) / J&J 
Welcome,         Profile    Billing    Logout  
 97 Diseases   247 Trials   247 Trials   14602 News 


«12...2122232425262728293031...170171»
  • ||||||||||  rivaroxaban / Generic mfg., enoxaparin sodium / Generic mfg.
    RECURRENT VENOUS THROMBOEMBOLIC DISEASE IN A PATIENT WITH SEVERE CONGENITAL FACTOR XIII DEFICIENCY () -  Feb 13, 2023 - Abstract #EAHAD2023EAHAD_480;    
    The primary objective is to evaluate the hemostatic effectiveness of a 4F-PCC (Prothromplex Total At the age of 36, she had an uneventful pregnancy with a venous thromboprophylaxis by enoxaparin throughout the pregnancy and a concomitant FXIII supplementation (Fibrogammin
  • ||||||||||  Berinert (C1 esterase inhibitor (human) IV) / CSL Behring
    SPECIFIC MEASUREMENT OF ACTIVATED COAGULATION FACTORS BY COMPLEX FORMATION WITH PROTEASE INHIBITORS () -  Feb 13, 2023 - Abstract #EAHAD2023EAHAD_260;    
    Here we describe the use of solid phase-bound inhibitors (tissue factor pathway inhibitor [TFPI], corn trypsin inhibitor [CTI], and C1-inhibitor [C1-inh]) to measure the activated coagulation factors factor X (FXa), factor XII (FXIIa) and factor XI (FXIa) by formation of the immobilized inhibitor-protease complex and its immunological detection by protease-specific antibody. TFPI (R&D Systems), CTI (ERL) and purified plasma-derived C1-inh (Berinert, CSL Behring), diluted in phosphate-buffered saline (PBS) to a concentration of 10 ?g/mL were coated to Maxisorp F96 plates at 4
  • ||||||||||  rivaroxaban / Generic mfg.
    Journal:  Reduced- or Half-Dose Rivaroxaban Following Left Atrial Appendage Closure: A Feasible Antithrombotic Therapy in Patients at High Risk of Bleeding? (Pubmed Central) -  Feb 12, 2023   
    The incidence of major bleeding was significantly higher in the warfarin group than in either the reduced- or half-dose rivaroxaban groups (warfarin vs. rivaroxaban 15 mg: 2.6% vs. 0%, p = 0.030; warfarin vs. rivaroxaban 10 mg: 2.6% vs. 0%, p = 0.038). Either reduced- or half-dose rivaroxaban may be an effective and safe alternative to warfarin therapy in patients with LAAC and who are at high risk of bleeding, the risk of thromboembolism being similar and of major bleeding lower for both doses of rivaroxaban.
  • ||||||||||  Savaysa (edoxaban) / Daiichi Sankyo
    PK/PD data, Review, Journal:  Pharmacokinetics and Dosing Regimens of Direct Oral Anticoagulants in Morbidly Obese Patients: An Updated Literature Review. (Pubmed Central) -  Feb 11, 2023   
    Standard dosing of apixaban or rivaroxaban is effective and safe for VTE and AF patients with morbid obesity. Trough edoxaban concentration and anti-Xa activity were similar in different BMI groups (18.5 to >40?kg/m), and standard dosing of edoxaban may be effective and safe for AF patients.Current evidence suggests dabigatran should be used with caution in patients with AF as it might increase the risk of gastrointestinal bleeding; Standard dosing of apixaban or rivaroxaban can be used in VTE or AF patients; Standard dosing of edoxaban may be considered in AF patients.
  • ||||||||||  rivaroxaban / Generic mfg., aprotinin / Generic mfg.
    A sensitive and selective method for the measurement of activated factor X based on complex formation with tissue factor pathway inhibitor (#14) (foyer) -  Feb 8, 2023 - Abstract #GTH2023GTH_338;    
    After a washing step with PBS containing 0.05% Tween 20 (PBST), plates were blocked with PBST containing 0.5% skimmed dry milk, 3 mM EDTA and 120 KIU aprotinin: This buffer was also used as dilution buffer for samples and purified FXa (Haematologic Technologies), used as the assay standard...Addition of the FXa-specific synthetic inhibitor Rivaroxaban caused complete signal inhibition with a 50% inhibition rate elicited at a concentration of 177 ng/mL...Inter-run precision determined in six separate measurements for four aPPC lots ranged from 3.7% to 5.4%. Conclusion The TFPI-FXa complex formation assay described enables for a sensitive, robust, and reliable FXa measurement with high selectivity for FXa.
  • ||||||||||  Expression and release of tumor cell tissue factor triggers recurrent thromboembolism in a patient with endometrial cancer (#24) (foyer) -  Feb 8, 2023 - Abstract #GTH2023GTH_333;    
    Results Despite therapeutic anticoagulation with various agents, including rivaroxaban, fondaparinux and low-molecular-weight heparin (LMWH), the patient experienced recurrent venous and arterial thromboembolism with at least seven distinct thromboembolic events within 3 months...Thus, anticoagulation was continued with the LMWH, enoxaparin...No further thrombotic events have occurred. Conclusion Continuous anticoagulation with argatroban and multimodal anticancer treatment may be necessary to control TF-driven paraneoplastic coagulation activation with recurrent CAT in endometrial cancer.
  • ||||||||||  AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
    Predictors Of Intracranial Hemorrhage Volume Expansion In Patients Receiving Factor Xa Inhibitors In The Annexa-4 Trial (Hall F, Poster Hall; P126) -  Feb 7, 2023 - Abstract #ISC2023ISC_823;    
    Shorter time from onset of symptoms to CT, lower GCS score and larger hematoma volumes at presentation increased the probability of ICrH expansion in FXa-associated ICrH treated with andexanet. These findings can inform the eligibility criteria of clinical trials targeting hemostatic efficacy in patients with FXa-associated ICrH.
  • ||||||||||  Sulonex (sulodexide) / Alfasigma
    Endothelial Repair, A Promising Target for the Acute Approach of Deep Venous Thrombosis Management (La Cantera Ballroom) -  Feb 5, 2023 - Abstract #AVF2023AVF_153;    
    This agent seems to significantly accelerate the thrombolytic process and decrease the systemic and local inflammatory reaction provoked during the acute period of DVT and it also has some influence on the appearance and severity of post thrombotic syndrome. It is a secure adjuvant to new oral anticoagulants accelerating the recovery process of the patients with this problem.
  • ||||||||||  Review, Journal:  Anticoagulation for Atrial Fibrillation: A Review of Current Literature and Views. (Pubmed Central) -  Feb 3, 2023   
    One major concern and disadvantage for DOACs was lack of reversal agents, which have largely been ameliorated by the approval of Idarucizumab for dabigatran and Andexanet alfa for both apixaban and rivaroxaban, with Ciraparantag as a universal reversal agent for all DOACs undergoing Fast-Track Review from FDA. In this article, we will be providing a broad review of anticoagulation for atrial fibrillation with a focus on risk stratification schemes and anticoagulation agents (warfarin, aspirin, DOACs) including special clinical considerations.
  • ||||||||||  Savaysa (edoxaban) / Daiichi Sankyo
    Review, Journal:  A Review of the Past, Present and Future of Cancer-associated Thrombosis Management. (Pubmed Central) -  Feb 2, 2023   
    This has led to a change in treatment paradigms so that direct-acting oral anticoagulants are now considered first-line agents in appropriately selected patients. In this article, we review the prior and recent landmark studies that have directed the treatment of cancer-associated thrombosis, and discuss specific factors that affect management as well as future treatment considerations.
  • ||||||||||  rivaroxaban / Generic mfg.
    Journal:  Angiology and hemostasis : what's new in 2022 (Pubmed Central) -  Feb 2, 2023   
    Thus, we discuss the issue of the treatment with rivaroxaban of atrial fibrillation associated with rheumatic valvulopathy, which has been studied in a randomized trial, the intensity of thromboprophylaxis in COVID outpatients and inpatients, and the bleeding risk of anticoagulation in patients with cerebral tumors. Finally, recent data on gene therapy in severe hemophilia A, an upcoming treatment, are discussed.
  • ||||||||||  rivaroxaban / Generic mfg., apixaban / Generic mfg.
    Retrospective data, Review, Journal:  Optimal Anticoagulation on TAVI Patients Based on Thrombotic and Bleeding Risk and the Challenge Beyond: A Systematic Review and Meta-Analysis. (Pubmed Central) -  Feb 2, 2023   
    In the category of patients without prior indication to anticoagulation, SAPT was proven safer and still effective, when antiplatelet therapies were compared, while a comparison of antiplatelet versus anticoagulation strategies noted the first one, with limited data, as the optimal one. Lastly, direct oral anticoagulants were shown to be safe substitutes for vitamin K antagonists for patients with prior indication to anticoagulation.
  • ||||||||||  Journal:  Safety of Continuing Anticoagulation Prior to Cardiac Catheterization in Pediatric Patients: A Los Angeles Center Experience. (Pubmed Central) -  Feb 2, 2023   
    Our single-center data suggest that performing cardiac catheterization on pediatric patients while on uninterrupted anticoagulation is safe and does not substantially increase the risk of bleeding complications based on a cohort of patients that varied in age, size, diagnosis, medical complexity, and type of intervention performed. Patients on warfarin therapy for a mechanical valve are most likely to benefit from this practice, as the ability to continue warfarin therapy avoids the need for bridging and other interruption-related complications.
  • ||||||||||  rivaroxaban / Generic mfg.
    Journal:  Anticoagulation for rheumatic mitral stenosis, INVICTUS in perspective. (Pubmed Central) -  Feb 1, 2023   
    VKA remains the standard of care for patients with moderate to severe rheumatic MS who have concomitant AF. Rates of stroke in anticoagulated patients with rheumatic MS and AF are lower than what is traditionally held, while nonstroke related deaths remain the most common mechanism of mortality.
  • ||||||||||  rivaroxaban / Generic mfg., prednisone / Generic mfg., argatroban / Generic mfg.
    Journal:  Long VITT: A case report. (Pubmed Central) -  Jan 30, 2023   
    Rivaroxaban was then initiated for the acute treatment and continued for the secondary prevention of recurrent events...Additional data is needed to offer optimal long-term management for this patient population. We suggest that long VITT diagnosis definition might include the persistence within patient serum/plasma of anti-PF4 platelet-activating antibodies with clinical manifestations (e.g., thrombocytopenia) for more than 3 months.